From the Guidelines
The pathologic complete response rate for triple-negative breast cancer after neoadjuvant chemotherapy with Nelarabine (Arranon) is not supported by the provided evidence, and therefore, the use of Nelarabine in this context is not recommended. The provided evidence does not mention Nelarabine (Arranon) as a treatment option for triple-negative breast cancer [ 1 ].
Key Points to Consider
- The correlation between pathologic response and long-term outcome is strongest for triple-negative breast cancer (TNBC) [ 1 ].
- A number of chemotherapy regimens have activity in the preoperative setting, but Nelarabine is not mentioned [ 1 ].
- Patients with triple-negative breast cancer may benefit from standard neoadjuvant chemotherapy regimens, which typically include anthracyclines and taxanes [ 1 ].
Treatment Options
- Standard neoadjuvant chemotherapy regimens for TNBC, such as dose-dense AC-T (doxorubicin/cyclophosphamide followed by paclitaxel) or carboplatin-based combinations, may be considered [ 1 ].
- The addition of platinum agents like carboplatin to standard regimens can increase pathologic complete response rates in TNBC [ 1 ].
Importance of Pathologic Complete Response
- Achieving pathologic complete response is particularly important in TNBC as it strongly correlates with improved long-term outcomes, including disease-free and overall survival [ 1 ].
From the Research
Pathologic Complete Response Rate for Triple-Negative Breast Cancer
The provided studies do not specifically mention the use of Nelarabine (Arranon) in neoadjuvant chemotherapy for triple-negative breast cancer.
- The studies 2, 3, 4, 5, 6 discuss various aspects of triple-negative breast cancer, including pathological complete response rates, survival outcomes, and predictive markers of response to neoadjuvant chemotherapy.
- However, none of these studies mention the use of Nelarabine (Arranon) in the treatment of triple-negative breast cancer.
- As a result, there is no available data on the pathologic complete response rate for triple-negative breast cancer after neoadjuvant chemotherapy with Nelarabine (Arranon) based on the provided evidence.
Available Data on Pathologic Complete Response Rates
- Study 4 reports a pathologic complete response rate of 55% in patients with triple-negative breast cancer treated with neoadjuvant carboplatin plus docetaxel.
- Study 2 reports a pathologic complete response rate of 32.5% in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy, with 57.7% of patients with BRCA1/2 pathogenic variants achieving a pathologic complete response.
- Study 5 reports a 10-year overall survival rate of 78% and a 10-year disease-free survival rate of 97% in patients with triple-negative breast cancer who achieved a pathologic complete response after neoadjuvant chemotherapy.
- Study 6 reports that around 40-50% of patients with triple-negative breast cancer achieve a pathological complete response after treatment with neoadjuvant chemotherapy.